Two infectious‑disease advances reported this week could shift treatment paradigms: Novartis and MMV presented positive Phase 3 results for GanLum (ganaplacide + lumefantrine), a novel mechanism antimalarial that cured 97.4% of participants and outperformed standard therapy across African study sites. The late‑stage data were presented at ASTMH and position GanLum as a candidate to counter rising artemisinin resistance. Separately, researchers disclosed a novel small molecule inhibitor targeting OmpV in Vibrio cholerae, showing preclinical efficacy against cholera by disrupting an understudied outer membrane protein. The cholera inhibitor represents an antibiotic strategy that targets pathogen virulence and dispersal mechanisms rather than classical bactericidal pathways. Taken together, the developments highlight renewed investment in next‑generation anti‑infectives and alternative antibiotic modalities—areas of intensified focus amid global resistance pressures and pandemic preparedness agendas.